Dynavax (DVAX) Stock Forecast, Price Target & Predictions
DVAX Stock Forecast
Dynavax stock forecast is as follows: an average price target of $24.50 (represents a 107.80% upside from DVAX’s last price of $11.79) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
DVAX Price Target
The average price target for Dynavax (DVAX) is $24.50 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $29.00 to $20.00. This represents a potential 107.80% upside from DVAX's last price of $11.79.
DVAX Analyst Ratings
According to 3 Wall Street analysts, Dynavax's rating consensus is 'Buy'. The analyst rating breakdown for DVAX stock is 0 'Strong Buy' (0.00%), 2 'Buy' (66.67%), 1 'Hold' (33.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Dynavax Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 28, 2024 | Edward White | H.C. Wainwright | $29.00 | $11.37 | 155.06% | 145.97% |
| May 14, 2024 | Paul Choi | Goldman Sachs | $20.00 | $11.00 | 81.82% | 69.64% |
The latest Dynavax stock forecast, released on Jun 28, 2024 by Edward White from H.C. Wainwright, set a price target of $29.00, which represents a 155.06% increase from the stock price at the time of the forecast ($11.37), and a 145.97% increase from DVAX last price ($11.79).
Dynavax Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 2 |
| Avg Price Target | - | - | $24.50 |
| Last Closing Price | $11.79 | $11.79 | $11.79 |
| Upside/Downside | -100.00% | -100.00% | 107.80% |
In the current month, the average price target of Dynavax stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Dynavax's last price of $11.79. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 15, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jun 28, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| May 14, 2024 | Goldman Sachs | Neutral | Neutral | Hold |
| May 14, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Feb 24, 2023 | JMP Securities | Market Outperform | Market Outperform | Hold |
| Sep 27, 2022 | JMP Securities | - | Outperform | Initialise |
Dynavax's last stock rating was published by H.C. Wainwright on Oct 15, 2024. The company gave DVAX a "Buy" rating, the same as its previous rate.
Dynavax Financial Forecast
Dynavax Revenue Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $69.51M | $60.25M | $46.92M | $184.49M | $167.74M | $256.46M | $113.99M | $195.07M | $108.27M | $52.77M | $83.33M | $19.55M | $13.41M |
| Avg Forecast | $106.32M | $133.66M | $126.67M | $107.33M | $90.49M | $112.42M | $105.29M | $86.89M | $75.45M | $92.46M | $86.66M | $69.79M | $72.44M | $84.17M | $76.04M | $54.98M | $52.73M | $60.30M | $48.39M | $38.58M | $179.60M | $159.41M | $150.99M | $154.29M | $208.87M | $58.22M | $41.60M | $59.11M | $13.06M | $9.44M |
| High Forecast | $106.32M | $133.66M | $126.67M | $107.33M | $90.49M | $112.42M | $105.29M | $86.89M | $75.45M | $92.46M | $86.66M | $69.79M | $72.44M | $84.90M | $76.04M | $54.98M | $54.73M | $66.01M | $48.39M | $38.58M | $179.60M | $159.41M | $150.99M | $154.29M | $208.87M | $58.22M | $41.60M | $59.11M | $13.06M | $9.44M |
| Low Forecast | $106.32M | $133.66M | $126.67M | $107.33M | $90.49M | $112.42M | $105.29M | $86.89M | $75.45M | $92.46M | $86.66M | $69.79M | $72.44M | $83.42M | $76.04M | $54.98M | $50.71M | $58.29M | $48.39M | $38.58M | $179.60M | $159.41M | $150.99M | $154.29M | $208.87M | $58.22M | $41.60M | $59.11M | $13.06M | $9.44M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 2 | 4 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 3 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.15% | 1.25% | 1.22% | 1.03% | 1.05% | 1.70% | 0.74% | 0.93% | 1.86% | 1.27% | 1.41% | 1.50% | 1.42% |
Dynavax's average Quarter revenue forecast for Dec 23 based on 2 analysts is $52.73M, with a low forecast of $50.71M, and a high forecast of $54.73M. DVAX's average Quarter revenue forecast represents a -24.15% decrease compared to the company's last Quarter revenue of $69.51M (Sep 23).
Dynavax EBITDA Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 2 | 4 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 3 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $5.12M | $-3.40M | $-9.72M | $69.66M | $68.91M | $130.41M | $34.47M | $102.37M | $-24.99M | $9.35M | $7.36M | $-8.90M | $10.94M |
| Avg Forecast | $-24.95M | $-31.36M | $-29.72M | $-25.18M | $-21.23M | $-26.38M | $-24.71M | $-20.39M | $-17.70M | $-21.70M | $-20.34M | $-16.38M | $-17.00M | $-19.75M | $-17.84M | $54.67M | $-12.37M | $-14.15M | $-11.35M | $-9.05M | $109.17M | $-37.40M | $-35.43M | $39.29M | $-49.01M | $-13.66M | $-9.76M | $16.56M | $-3.07M | $-2.21M |
| High Forecast | $-24.95M | $-31.36M | $-29.72M | $-25.18M | $-21.23M | $-26.38M | $-24.71M | $-20.39M | $-17.70M | $-21.70M | $-20.34M | $-16.38M | $-17.00M | $-19.57M | $-17.84M | $65.61M | $-11.90M | $-13.68M | $-11.35M | $-9.05M | $131.01M | $-37.40M | $-35.43M | $47.15M | $-49.01M | $-13.66M | $-9.76M | $19.88M | $-3.07M | $-2.21M |
| Low Forecast | $-24.95M | $-31.36M | $-29.72M | $-25.18M | $-21.23M | $-26.38M | $-24.71M | $-20.39M | $-17.70M | $-21.70M | $-20.34M | $-16.38M | $-17.00M | $-19.92M | $-17.84M | $43.74M | $-12.84M | $-15.49M | $-11.35M | $-9.05M | $87.34M | $-37.40M | $-35.43M | $31.43M | $-49.01M | $-13.66M | $-9.76M | $13.25M | $-3.07M | $-2.21M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.36% | 0.30% | 1.07% | 0.64% | -1.84% | -3.68% | 0.88% | -2.09% | 1.83% | -0.96% | 0.44% | 2.90% | -4.94% |
2 analysts predict DVAX's average Quarter EBITDA for Dec 23 to be $-12.37M, with a high of $-11.90M and a low of $-12.84M. This is -341.83% lower than Dynavax's previous annual EBITDA (Sep 23) of $5.12M.
Dynavax Net Income Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 2 | 4 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 3 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $14.29M | $3.43M | $-24.33M | $67.73M | $63.81M | $128.75M | $32.86M | $101.39M | $-28.43M | $4.47M | $891.00K | $-15.47M | $4.40M |
| Avg Forecast | $20.03M | $36.45M | $32.72M | $20.68M | $12.79M | $26.20M | $22.44M | $11.91M | $5.19M | $15.79M | $16.84M | $4.27M | $6.30M | $17.50M | $9.97M | $49.53M | $-1.63M | $-5.83M | $-14.34M | $45.03M | $106.41M | $45.83M | $35.14M | $35.60M | $98.86M | $3.86M | $-5.66M | $2.00M | $-37.84M | $-31.41M |
| High Forecast | $20.03M | $36.45M | $32.72M | $20.68M | $12.79M | $26.20M | $22.44M | $11.91M | $5.19M | $15.79M | $16.84M | $4.27M | $6.30M | $21.00M | $10.00M | $59.44M | $1.63M | $23.33M | $-14.34M | $54.04M | $127.70M | $45.83M | $35.14M | $42.72M | $98.86M | $3.86M | $-5.66M | $2.41M | $-37.84M | $-31.41M |
| Low Forecast | $20.03M | $36.45M | $32.72M | $20.68M | $12.79M | $26.20M | $22.44M | $11.91M | $5.19M | $15.79M | $16.84M | $4.27M | $6.30M | $14.00M | $9.93M | $39.63M | $-4.89M | $-40.83M | $-14.34M | $36.02M | $85.13M | $45.83M | $35.14M | $28.48M | $98.86M | $3.86M | $-5.66M | $1.60M | $-37.84M | $-31.41M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.45% | -0.24% | -0.54% | 0.64% | 1.39% | 3.66% | 0.92% | 1.03% | -7.36% | -0.79% | 0.44% | 0.41% | -0.14% |
Dynavax's average Quarter net income forecast for Dec 23 is $-1.63M, with a range of $-4.89M to $1.63M. DVAX's average Quarter net income forecast represents a -111.41% decrease compared to the company's last Quarter net income of $14.29M (Sep 23).
Dynavax SG&A Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 2 | 4 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 3 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $38.05M | $37.07M | $36.54M | $31.02M | $32.04M | $36.18M | $32.17M | $29.22M | $26.93M | $21.58M | $22.42M | $17.84M | $29.24M |
| Avg Forecast | $104.19M | $130.99M | $124.13M | $105.18M | $88.68M | $110.17M | $103.19M | $85.15M | $73.94M | $90.61M | $84.93M | $68.40M | $70.99M | $82.48M | $74.52M | $48.50M | $51.67M | $59.09M | $47.42M | $37.81M | $31.17M | $156.22M | $147.97M | $34.85M | $204.69M | $57.05M | $40.77M | $50.45M | $12.80M | $9.25M |
| High Forecast | $104.19M | $130.99M | $124.13M | $105.18M | $88.68M | $110.17M | $103.19M | $85.15M | $73.94M | $90.61M | $84.93M | $68.40M | $70.99M | $83.20M | $74.52M | $58.20M | $53.64M | $64.69M | $47.42M | $37.81M | $37.40M | $156.22M | $147.97M | $41.82M | $204.69M | $57.05M | $40.77M | $60.54M | $12.80M | $9.25M |
| Low Forecast | $104.19M | $130.99M | $124.13M | $105.18M | $88.68M | $110.17M | $103.19M | $85.15M | $73.94M | $90.61M | $84.93M | $68.40M | $70.99M | $81.75M | $74.52M | $38.80M | $49.69M | $57.12M | $47.42M | $37.81M | $24.93M | $156.22M | $147.97M | $27.88M | $204.69M | $57.05M | $40.77M | $40.36M | $12.80M | $9.25M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.64% | 0.78% | 0.97% | 1.00% | 0.21% | 0.24% | 0.92% | 0.14% | 0.47% | 0.53% | 0.44% | 1.39% | 3.16% |
Dynavax's average Quarter SG&A projection for Dec 23 is $51.67M, based on 2 Wall Street analysts, with a range of $49.69M to $53.64M. The forecast indicates a 35.78% rise compared to DVAX last annual SG&A of $38.05M (Sep 23).
Dynavax EPS Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 2 | 4 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 3 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $0.11 | $0.03 | $-0.19 | $0.53 | $0.50 | $1.02 | $0.26 | $0.84 | $-0.24 | $0.04 | $0.01 | $-0.14 | $0.04 |
| Avg Forecast | $0.13 | $0.24 | $0.21 | $0.13 | $0.08 | $0.17 | $0.15 | $0.08 | $0.03 | $0.10 | $0.11 | $0.03 | $0.04 | $0.11 | $0.06 | $-0.02 | $-0.01 | $-0.04 | $-0.09 | $-0.13 | $0.41 | $0.30 | $0.23 | $0.28 | $0.64 | $0.03 | $-0.04 | $-0.03 | $-0.24 | $-0.20 |
| High Forecast | $0.13 | $0.24 | $0.21 | $0.13 | $0.08 | $0.17 | $0.15 | $0.08 | $0.03 | $0.10 | $0.11 | $0.03 | $0.04 | $0.14 | $0.06 | $-0.02 | $0.01 | $0.15 | $-0.09 | $-0.13 | $0.41 | $0.30 | $0.23 | $0.28 | $0.64 | $0.03 | $-0.04 | $-0.03 | $-0.24 | $-0.20 |
| Low Forecast | $0.13 | $0.24 | $0.21 | $0.13 | $0.08 | $0.17 | $0.15 | $0.08 | $0.03 | $0.10 | $0.11 | $0.03 | $0.04 | $0.09 | $0.06 | $-0.02 | $-0.03 | $-0.26 | $-0.09 | $-0.13 | $0.41 | $0.30 | $0.23 | $0.28 | $0.64 | $0.03 | $-0.04 | $-0.03 | $-0.24 | $-0.20 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.91% | -0.29% | 1.43% | 1.29% | 1.69% | 4.48% | 0.93% | 1.31% | -9.60% | -1.09% | -0.40% | 0.57% | -0.20% |
According to 2 Wall Street analysts, Dynavax's projected average Quarter EPS for Dec 23 is $-0.01, with a low estimate of $-0.03 and a high estimate of $0.01. This represents a -109.60% decrease compared to DVAX previous annual EPS of $0.11 (Sep 23).
Dynavax Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| EBS | Emergent BioSolutions | $8.77 | $51.50 | 487.23% | Buy |
| IRWD | Ironwood Pharmaceuticals | $4.19 | $11.67 | 178.52% | Buy |
| PCRX | Pacira BioSciences | $16.45 | $40.00 | 143.16% | Hold |
| DVAX | Dynavax | $11.79 | $24.50 | 107.80% | Buy |
| AQST | Aquestive Therapeutics | $5.15 | $9.50 | 84.47% | Buy |
| ANIP | ANI Pharmaceuticals | $56.01 | $79.00 | 41.05% | Buy |
| AMPH | Amphastar Pharmaceuticals | $50.59 | $66.00 | 30.46% | Buy |
| ALKS | Alkermes | $26.59 | $34.38 | 29.30% | Hold |
| COLL | Collegium Pharmaceutical | $32.72 | $41.50 | 26.83% | Buy |
| LNTH | Lantheus | $115.45 | $146.25 | 26.68% | Buy |
| NBIX | Neurocrine Biosciences | $120.53 | $147.70 | 22.54% | Buy |
| ITCI | Intra-Cellular Therapies | $86.17 | $94.50 | 9.67% | Buy |
| DCPH | Deciphera Pharmaceuticals | $25.59 | $26.32 | 2.85% | Hold |
DVAX Forecast FAQ
Is Dynavax a good buy?
Yes, according to 3 Wall Street analysts, Dynavax (DVAX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 66.67% of DVAX's total ratings.
What is DVAX's price target?
Dynavax (DVAX) average price target is $24.5 with a range of $20 to $29, implying a 107.80% from its last price of $11.79. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Dynavax stock go up soon?
According to Wall Street analysts' prediction for DVAX stock, the company can go up by 107.80% (from the last price of $11.79 to the average price target of $24.5), up by 145.97% based on the highest stock price target, and up by 69.64% based on the lowest stock price target.
Can Dynavax stock reach $20?
DVAX's average twelve months analyst stock price target of $24.5 supports the claim that Dynavax can reach $20 in the near future.
What are Dynavax's analysts' financial forecasts?
Dynavax's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $395.09M (high $395.09M, low $395.09M), average EBITDA is $-92.706M (high $-92.706M, low $-92.706M), average net income is $73.34M (high $73.34M, low $73.34M), average SG&A $387.18M (high $387.18M, low $387.18M), and average EPS is $0.475 (high $0.475, low $0.475). DVAX's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $473.98M (high $473.98M, low $473.98M), average EBITDA is $-111M (high $-111M, low $-111M), average net income is $109.89M (high $109.89M, low $109.89M), average SG&A $464.49M (high $464.49M, low $464.49M), and average EPS is $0.711 (high $0.711, low $0.711).
Did the DVAX's actual financial results beat the analysts' financial forecasts?
Based on Dynavax's last annual report (Dec 2022), the company's revenue was $722.68M, beating the average analysts forecast of $644.29M by 12.17%. Apple's EBITDA was $298.23M, beating the average prediction of $75.63M by 294.34%. The company's net income was $293.16M, beating the average estimation of $222.98M by 31.47%. Apple's SG&A was $131.41M, missing the average forecast of $370.21M by -64.50%. Lastly, the company's EPS was $2.91, beating the average prediction of $1.22 by 139.31%. In terms of the last quarterly report (Sep 2023), Dynavax's revenue was $69.51M, beating the average analysts' forecast of $60.3M by 15.28%. The company's EBITDA was $5.12M, missing the average prediction of $-14.149M by -136.16%. Dynavax's net income was $14.29M, missing the average estimation of $-5.833M by -345.05%. The company's SG&A was $38.05M, missing the average forecast of $59.09M by -35.60%. Lastly, the company's EPS was $0.11, missing the average prediction of $-0.0378 by -391.31%